Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Recurrence 4Breast Neoplasms 4Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Colorectal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Brain Neoplasms 1Alopecia 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 76Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Immunoconjugates × Clear all
NCT03255070 2024-02-01

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Ambrx, Inc.

Phase 1 Completed
106 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡